In this video, health-care analyst David Williamson discusses how Big Pharma is attempting to catch up when it comes to creating a next-gen hepatitis-C cure. Today's news features a collaboration between Merck and Bristol-Myers Squibb. Has Big Pharma missed the boat, or is there still time to get on board with a winning combination? Watch and find out.
Can Merck beat the patent cliff?
This titan of the pharmaceutical industry stumbled into 2013 and continues to battle patent expirations and pipeline problems. Is Merck still a solid dividend play, or should investors be looking elsewhere? In a new premium research report on Merck, The Fool tackles all of the company's moving parts, its major market opportunities, and reasons to both buy and sell. To find out more click here to claim your copy today.